Healthy Skepticism Library

Items published in 2005

There are 1256 items in the Healthy Skepticism Library that were published in 2005.

Page 12 of 13 pages ‹ First  < 10 11 12 13 > 

HSL1909
Moynihan R.
The marketing of a disease: female sexual dysfunction.
BMJ 2005 Jan 22; 330:(7484):192-4
http://bmj.bmjjournals.com/cgi/content/full/330/7484/192

HSL761
Tomlinson , H .
Novartis sucked into Serious Frauds Office inquiry Crackdown on alleged price-fixing cartels is widened
The Guardian 2005 Jan 21

HSL795
Many Americans Seek Drug Information - But Not Drugs - Online
News Briefs 2005 Jan 21

HSL760
Editorial .
India's Choice
The New York Times 2005 Jan 18

HSL1029
Lexchin J.
Prescribing errors
CMAJ 2005 Jan 18; 172:(2):
http://www.cmaj.ca/cgi/content/full/172/2/229

HSL1031
Lexchin J, Cassels A.
Does the C in CME stand for "Continuing" or "Commercial"?
CMAJ 2005 Jan 18; 172:(2):160-2
http://www.cmaj.ca/cgi/content/full/172/2/160-a

HSL757
Meier B .
Dispute Puts a Medical Journal Under Fire
The New York Times 2005 Jan 17

HSL758
Rowland , C .
Drug firms seek profit in giveaways: Marketing targets consumer loyalty
The Boston Globe 2005 Jan 17

HSL759
Two Drug Firms Set To Repatriate Profits
The Wall Street Journal 2005 Jan 17

HSL756
Saul , S .
F.D.A. Panel Votes Against Sale of Statins Over Counter
The New York Times 2005 Jan 15

HSL3800
Sams-Dodd F.
Target-based drug discovery: is something wrong?
Drug Discov Today 2005 Jan 15; 10:(2):139-47
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T64-4FGWYRP-F&_coverDate=01%2F15%2F2005&_alid=362933608&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5020&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=a783f5c6ceb7d3e498ae75801d03fda9

HSL3801
Lawrence R.
New opportunities in Asia: a focus on India and China.
Drug Discov Today 2005 Jan 15; 10:(2):89-91
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T64-4FGWYRP-6&_coverDate=01%2F15%2F2005&_alid=362934848&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5020&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=4d53ce3a1764cb7e12a6d44c2c452e52

HSL753
Prozac: A class action lawsuit is filed in Montreal
Canda News Wire Group 2005 Jan 14

HSL754
Herbert , B .
A Gift for Drug Makers
THE NEW YORK TIMES 2005 Jan 14

HSL748
Abboud , L .
Eli Lilly Goes On the Offensive To Defend Prozac
THE WALL STREET JOURNAL 2005 Jan 13

HSL749
Hospitals Step Up Efforts To Avoid Medication Errors
The Wall Street Journal 2005 Jan 12

HSL1199
Liberals threaten Canadian internet pharmacy industry
2005 Jan 12

HSL750
Abboud , L .
Challenge to Pfizer's Lipitor Has Some Investors Worried
The Wall Street Journal 2005 Jan 11

HSL751
Goozner , M .
Plugging The Whistle
TomPaine.com Daily Dispatch 2005 Jan 11

HSL769
Metherell M.
Call for more data on drug approvals
Political Correspondent 2005 Jan 11

HSL747
Tomlinson , H .
Regulators will be wary weighing up fatbuster: Sanofi is confident it has a winner with obesity drug but it can expect close scrutiny of side-effects
The Guardian 2005 Jan 10

HSL752
Hirschler , B .
Cholesterol lowering drug, Crestor Linked to Patient Death
Reuters 2005 Jan 10

HSL744
Webb T.
Litigation culture threatens future of drugs industry, MPs warned
Independent Digital 2005 Jan 9

HSL746
Rowland C .
Drug firms lagging on openness; Despite vow, few studies publicized
The Boston Globe 2005 Jan 9

HSL741
Mercola.com
Crestor: No Truth in Advertising?
mercola.com 2005 Jan 8

HSL742
Mercola.com
Drug Company Empire Ready to Fall
Mercola.com 2005 Jan 8

HSL743
Mercola.com
Drug Giant Admits Another Arthritis Painkiller Increases Heart Risks
Mercola.com 2005 Jan 8

HSL745
Lenzer J .
US bill to shield drug companies from product liability
BMJ 2005 Jan 8

HSL734
Tomlinson , H .
Drug firms will publish all trial data
The Guardian 2005 Jan 7

HSL736
Editoral .
Another Malpractice
The Washington Post 2005 Jan 7

HSL738
Drug driving 'lethal' warning
BBC News 2005 Jan 7

HSL5150
Lundberg GD.
The Institute for One World Health--a not-for-profit pharmaceutical company.
MedGenMed 2005 Jan 7; 7:(1):61
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3052&uid=16369366&db=PubMed&url=http://www.medscape.com/viewarticle/496086

HSL737
California prescription drug plan offers Canada-sized discounts
Bloomberg News 2005 Jan 6

HSL1198
Global Industry Position On Disclosure of Information About Clinical Trials
IFPMA 2005 Jan 6

HSL731
Rost P .
Contradicting itself on drug imports
The New Jersey Star-Ledger 2005 Jan 5

HSL732
Opera Singer Talks About Addiction
jointogether.org 2005 Jan 5

HSL733
Fuhrmann , M .
Health Canada defends drug-approval process, denies 'built-in bias'
Canadian Press 2005 Jan 5

HSL735
The ASSOCIATED.
Lilly Says Prozac Documents Contain No New Information
The New York Times 2005 Jan 5

HSL755
Vandehei , J .
Malpractice Bill Shields Drugmakers
THE WASHINGTON POST 2005 Jan 5

HSL729
Watkins , T .
Papers indicate firm knew possible Prozac suicide risk
CNN 2005 Jan 4

HSL728
Tsao A.
Big Changes for Big Pharma
Business Week 2005 Jan 3

HSL711
Konig , S .
Florida, Pfizer Team up to Improve Medicaid Patients' Use of Health Services
Health Care News 2005 Jan 1

HSL720
Belson , K .
Lilly Shares Fall on Report About Prozac Documents
THE NEW YORK TIMES 2005 Jan 1

HSL721
Bloomberg NEWS.
F.D.A. Approves Pfizer Remedy for Nerve Pain From Diabetes
The New York Times 2005 Jan 1

HSL2033
Mansfield PR, Mintzes B, Richards D, Toop L.
Direct to consumer advertising.
BMJ 2005 Jan 1; 330:(7481):5-6
http://bmj.bmjjournals.com/cgi/content/full/330/7481/5

HSL3792
Bloice C.
Why is this woman smiling? The hard sell of bad medicine.
Revolution 2005 Jan-Feb 01; 6:(1):22-9

HSL3804
Dalby AJ.
Reflections on the withdrawal of rofecoxib.
Cardiovasc J S Afr 2005 Jan-Feb 01; 16:(1):5-6
http://blues.sabinet.co.za/WebZ/Authorize?sessionid=0:autho=pubmed:password=pubmed2004&/AdvancedQuery?&format=F&next=images/ejour/cardio/cardio_v16_n1_a2.pdf

HSL5334
Frantz S.
How to avoid another 'Vioxx'.
Nat Rev Drug Discov 2005 Jan 01; 4:(1):5-7
http://www.nature.com/news/2004/041220/pf/nrd1629_pf.html

HSL1034
Lexchin JR.
Implications of pharmaceutical industry funding on clinical research.
Ann Pharmacother 2005 Jan; 39:(1):194-7
http://www.theannals.com/cgi/content/full/39/1/194

HSL1888
Hess R, Chang CC, Conigliaro J, McNeil M.
Understanding physicians' attitudes towards hormone therapy.
Womens Health Issues 2005 Jan-Feb; 15:(1):31-8
http://linkinghub.elsevier.com/retrieve/pii/S1049-3867(04)00103-3

HSL2072
Tibdewal S, Gupta M.
Mother's use of medication in their children of preschool age.
Indian J Public Health 2005 Jan-Mar; 49:(1):27-9

HSL2111
Meadows AB, Maine LL, Keyes EK, Pearson K, Finstuen K.
Pharmacy executive leadership issues and associated skills, knowledge, and abilities.
J Am Pharm Assoc (Wash DC) 2005 Jan-Feb; 45:(1):55-62

HSL4818
Granja M.
[Dangerous liaisons--physicians and pharmaceutical sales representatives].
Acta Med Port 2005 Jan-Feb; 18:(1):61-8
http://www.actamedicaportuguesa.com/pdf/2005-18/1/061-068.pdf

HSL4819
Brody H.
The company we keep: why physicians should refuse to see pharmaceutical representatives.
Ann Fam Med 2005 Jan-Feb; 3:(1):82-5
http://www.annfammed.org/cgi/content/full/3/1/82

HSL4952
Rataboli PV, Garg A.
Confusing brand names: nightmare of medical profession.
J Postgrad Med 2005 Jan-Mar; 51:(1):13-6
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3153&uid=15793332&db=PubMed&url=http://www.jpgmonline.com/article.asp?issn=0022-3859;year=2005;volume=51;issue=1;spage=13;epage=16;aulast=Rataboli

HSL11092
Patten S, Cipriani A, Brambilla , P , Nose , M .
International Dosage Differences in Fluoxetine Clinical Trials
The Canadian Journal of Psychiatry 2005 Jan; 50:(1):31-38

HSL15162
Granja M.
LIGAÇÕES PERIGOSAS - Os Médicos e os Delegados de Informação Médica [DANGEROUS LIAISONS – physicians and pharmaceutical sales representatives]
Acta Med Port 2005 Jan-Feb; 18:(1):61-68
http://www.actamedicaportuguesa.com/pdf/2005-18/1/061-068.pdf

HSL19782
Pai S
Changing attitudes to drug company sponsorship?
Indian J Med Ethics 2005 Jan; 2:(1):
http://www.ijme.in/131le028.html

HSL3601
Chodock R, Yolkut D, Connolly DR.
"Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions
Tort Trial Insur Pract Law J 2005 Spr 01; 40:(3):997-1017

HSL5141
Lacasse JR.
Consumer advertising of psychiatric medications biases the public against nonpharmacological treatment.
Ethical Hum Psychol Psychiatry 2005 Fal 01; 7:(3):175-9

HSL19375
Zipkin DA, Steinman MA
Interactions between pharmaceutical representatives and doctors in training. A thematic review.
J Gen Intern Med 2005; (8):777-86
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490177/?tool=pubmed

HSL1552
United Kingdom: Companies and organizations in this country ranked by total spending
Lobby Watch - The Center for Public Integrity 2005;
http://www.publicintegrity.org/lobby/profile-pf.aspx?act=countries&year=2003&co=uk

HSL1605
Randall ML, Rosenbaum JR, Rohrbaugh RM, Rosenheck RA.
Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention.
Acad Psychiatry 2005 Spr; 29:(1):33-9
http://ap.psychiatryonline.org/cgi/content/abstract/29/1/33

HSL1647
Mohl PC.
Psychiatric training program engagement with the pharmaceutical industry: an educational issue, not strictly an ethical one.
Acad Psychiatry 2005 Sum; 29:(2):215-21
http://ap.psychiatryonline.org/cgi/content/full/29/2/215

HSL19043
Schwartz LM, Woloshin S, Welch HG
Can patients interpret health information? An assessment of the medical data interpretation test.
Med Decis Making 2005; 25:(3):290-300
http://mdm.sagepub.com/content/25/3/290.long

HSL2331
Muijrers P, Grol R., Sijbrandij J, Janknegt R., Knottnerus J
Differences in prescribing between general practitioners.
Unpublished 2005;

HSL3710
Bezold C, Peck J.
Drug regulation 2056.
Food Drug Law J 2005; 60:(2):127-36
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Display&DB=pubmed

HSL3711
Zelenay JL Jr.
The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Food Drug Law J 2005; 60:(2):261-338

HSL3723
Manchanda P, Honka E.
The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):785-822
http://www.ncbi.nlm.nih.gov/pubmed/16052900

HSL3724
Chin MH.
The patient's role in choice of medications: direct-to-consumer advertising and patient decision aids.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):771-84

HSL3725
Epstein RA.
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):741-70

HSL3726
Eisenberg RS.
The problem of new uses.
Yale J Health Policy Law Ethics 2005 Sum; 5:(2):717-39

HSL3747
Benezet JP.
[Pharmaceutical containers and their technological feature at the end of the middle ages].
J Pharm Belg 2005; 60:(2):64-75

HSL3754
Elliott C.
Adventure! Comedy! Tragedy! Robots! How bioethicists learned to stop worrying and embrace their inner cyborgs.
J Bioeth Inq 2005; 2:(1):18-23

HSL3782
Maynard A.
Quality control in the regulation of pharmaceuticals.
Pharmacoeconomics 2005; 23:(5):421-2

HSL3790
Malhi GS, Mitchell PB, Berk M, Goodwin GM.
Mood stabilizers: a labile label.
Acta Psychiatr Scand Suppl 2005; (426):5-6

HSL19042
Woloshin S, Schwartz LM.
Reducing the risk that patients get it wrong.
Gastroenterology 2005; 129:(2):748-50
http://www.gastrojournal.org/article/S0016-5085(05)01197-2/abstract

HSL4580
McCann MA.
Dietary supplement labeling: cognitive biases, market manipulation & consumer choice.
Am J Law Med 2005; 31:(2-3):215-68

HSL4591
Christenson V.
Drug companies offer major discounts to uninsured.
J Law Med Ethics 2005 Summer; 33:(2):399-403

HSL4592
Falit B.
Pharma's commitment to maintaining a clinical trial register: increased transparency or contrived public appeasement?
J Law Med Ethics 2005 Summer; 33:(2):391-6

HSL4596
Kahn JP.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Sum; 5:(3):W13
http://taylorandfrancis.metapress.com/(iiz3n4n1mkazbl45vc3o1i45)/app/home/contribution.asp?referrer=parent&backto=issue,31,34;journal,6,24;linkingpublicationresults,1:111605,1

HSL4597
Elliott C.
Lessons in conflict of interest: the construction of the martyrdom of David Healy and the dilemma of bioethics.
Am J Bioeth 2005 Summer; 5:(3):
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006354&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W16

HSL4598
Andrews J.
U..S. Military sponsored vaccine trials and la resistance in Nepal.
Am J Bioeth 2005 Summer;5(3):W1-3 2005 Summer; 5:(3):W1-3
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3396&uid=16006352&db=PubMed&url=http://taylorandfrancis.metapress.com/openurl.asp?genre=article&issn=1526-5161&volume=5&issue=3&spage=W1

HSL4706
Cain DM, Loewenstein G, Moore DA.
The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest
The Journal of Legal Studies 2005; 34:1-25
http://www.cbdr.cmu.edu/mpapers/CainLoewensteinMoore2005.pdf

HSL4718
Maurer W.
Creative and innovative statistics in clinical research and development.
Methods Inf Med 2005; 44:(4):551-60

HSL4719
Kagan J.
Human morality and temperament.
Nebr Symp Motiv 2005; 51:1-32

HSL4727
Arrieta J.
[Off label prescription in nephrology]
Nefrologia 2005; 25:(2):103-5

HSL4747
Johnston RE.
Academic science and the business of vaccines.
Arch Virol Suppl 2005; (19):203-6

HSL4748
Halpern GM.
COX-2 inhibitors: a story of greed, deception and death.
Inflammopharmacology 2005; 13:(4):419-25
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3152&uid=16354394&db=PubMed&url=http://openurl.ingenta.com/content/nlm?genre=article&issn=0925-4692&volume=13&issue=4&spage=419&aulast=Halpern

HSL4749
Abrahams E, Ginsburg GS, Silver M.
The Personalized Medicine Coalition: goals and strategies.
Am J Pharmacogenomics 2005; 5:(6):345-55

HSL4786
Castresana L, Mejia R, Aznar M.
[The attitude of physicians regarding the promotion strategies of the pharmaceutical industry].
Medicina (B Aires) 2005; 65:(3):247-51

HSL4797
Chandra A, Miller M.
A closer look at the concept, historical overview, and value of direct-to-consumer advertising of prescription drugs.
Hosp Top 2005 Fall; 83:(4):32-6

HSL4828
Stiles GM.
Wyeth responds to criticism.
Md Med 2005 Aut; 6:(4):5,

HSL4834
Tomes N.
The great American medicine show revisited
Bull Hist Med. 2005 Winter;79(4):627-63 2005 Wint; 79:(4):627-63
http://www.ncbi.nlm.nih.gov/entrez/utils/lofref.fcgi?PrId=3354&uid=16327082&db=PubMed&url=http://muse.jhu.edu/cgi-bin/resolve_openurl.cgi?issn=0007-5140&volume=79&issue=4&spage=627&aulast=Tomes

HSL4838
Klanica K.
Conflicts of interest in medical research: how much conflict should exceed legal boundaries?
J Biolaw Bus 2005; 8:(3):37-45

HSL4847
Polonuer JL.
[Strategies for drug promotion].
Medicina (B Aires) 2005; 65:(4):373-6

HSL4857
van Mosseveld C.
Pharmaceutical expenditure compared across countries.
Can J Clin Pharmacol 2005 Fal; 12:(3):e269-75
http://www.cjcp.ca/pdf/CJCP_04-048_e269.pdf

HSL4880
Longest BB Jr, Rohrer WM.
Communication between public health agencies and their external stakeholders.
J Health Hum Serv Adm 2005 Fal; 28:(2):189-217

HSL4927
Caulfield T.
Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
Health Law Rev 2005; 13:(2-3):114-6

HSL4928
Caulfield T.
Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Health Law Rev 2005; 13:(2-3):58-61

Page 12 of 13 pages ‹ First  < 10 11 12 13 >